Infinite Brain Technologies (IBT) and ATLATL are working together to integrate brain health technology with AI. The aim is to advance the development of personalised precision digital therapeutics through integration with AI to provide more effective clinical solutions for individuals battling mental disorders.

The two companies are focusing on more affective treatments for mental health disorders which according to the WHO, affect around one in eight people worldwide. Nearly one billion people worldwide suffer from mental health problems, including depression, anxiety, and schizophrenia. In terms of neurodevelopmental disorders, the worldwide estimates of the prevalence of ADHD are 5-7% of the youth population, and about 1% of children have ASD.

China-based IBT Global is a specialist in Digital Therapeutics (DTx). The firm has a cross-functional team operating at the intersection of neuroscience and software technology to develop patient-facing software applications.

The ATLATL Centre for Innovation & Research is a global innovation research and development centre is creating a life sciences ecosystem by partnering with pharmaceutical companies, service companies, and venture capital firms.

Dr. Wei Sun, Founder and Chairman of IBT, made the following statement: “IBT’s team focuses on developing precise Digital Therapeutics for brain health globally and we are pleased and honoured to be partnering with ATLATL to develop precise digital therapeutics for brain health with advanced AI technologies.”

CEO of ATLATL, PC Zhu, expressed how ATLATL aims to make a significant contribution to the global brain health industry: “ATLATL is known for its infrastructure and operational management, specialised core facilities and on-site interactive research services. IBT is widely acknowledged for its ability to develop accurate digital therapeutics using advanced AI technologies and we are honoured to work with IBT to enhance global innovation in brain health.”

Justin Jia, CTO of IBT and CEO of IBT Global said: “We are thrilled to partner with ATLATL, leveraging its extensive R&D services and vast bio-tech networks, as we at IBT work towards our mission of creating cutting-edge AI-powered digital therapeutics. Our goal is to provide effective clinical solutions for individuals battling mental disorders.”

In March, IBT and Mohamed bin Zayed University of Artificial Intelligence announced a five-year research and development agreement. The two organisations have formed a a joint research lab to develop personalised Digital Therapeutics combined with AI for human brain health.